Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial
Previous studies have reported that tocotrienols (T3) possess many distinct properties such as antioxidant, cardioprotective, neuroprotective, anti-cancer, anti-inflammatory and anti-angiogenic, which are beneficial for the improvement of human health. However, there is limited data available on the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Malaysian Palm Oil Board
2016
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/47413/ http://psasir.upm.edu.my/id/eprint/47413/1/Safety%20assessment%20of%20tocotrienol%20supplementation%20in%20subjects%20with%20metabolic%20syndrome%20a%20randomised%20control%20trial.pdf |
| _version_ | 1848850810125942784 |
|---|---|
| author | Gan, Yee Lin Lai, Oi Ming Chew, Boon How Yuen, Kah Hay Nesaretnam, Kalanithi Teng, Kim Tiu Selvaduray, Kanga Rani Meganathan, Puvaneswari Fu, Ju Yen |
| author_facet | Gan, Yee Lin Lai, Oi Ming Chew, Boon How Yuen, Kah Hay Nesaretnam, Kalanithi Teng, Kim Tiu Selvaduray, Kanga Rani Meganathan, Puvaneswari Fu, Ju Yen |
| author_sort | Gan, Yee Lin |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Previous studies have reported that tocotrienols (T3) possess many distinct properties such as antioxidant, cardioprotective, neuroprotective, anti-cancer, anti-inflammatory and anti-angiogenic, which are beneficial for the improvement of human health. However, there is limited data available on the safety assessment of T3 compared to tocopherols (T). A randomised, double-blinded, cross-over and placebo-controlled human clinical trial was conducted to determine the safety and tolerance of T3 supplementation in 31 subjects with metabolic syndrome. The subjects were supplemented with tocotrienol-rich fraction (TRF) 200 mg or placebo capsules twice daily for two weeks followed by a post-intervention visit. Results showed that T3 supplementation had no significant adverse effect on the red blood cell (RBC), white blood cell (WBC) and platelet counts between TRF (5.10 ± 0.78 × 1012 litre-1, 7.35 ± 1.59 × 109 litre-1, 279.45 ± 73.86 × 109 litre-1, respectively) and placebo interventions (5.13 ± 0.76 × 1012 litre-1, 7.25 ± 1.95 × 109 litre-1, 267.45 ± 68.72 × 109 litre-1, respectively). Measures of serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT)) and albumin did not differ between TRF (25.68 ± 10.72 IU litre-1, 38.26 ± 24.74 IU litre-1, 43.61 ± 2.26 g litre-1, respectively) and placebo interventions (27.39 ± 16.44 IU litre-1, 42.23 ± 33.58 IU litre-1, 43.68 ± 2.15 g litre-1, respectively). This study indicated that supplementation with T3 at the dosage of 400 mg per day for 14 days did not induce haematoxicity and hepatotoxicity in subjects with metabolic syndrome. |
| first_indexed | 2025-11-15T10:12:12Z |
| format | Article |
| id | upm-47413 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T10:12:12Z |
| publishDate | 2016 |
| publisher | Malaysian Palm Oil Board |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-474132016-05-19T07:15:58Z http://psasir.upm.edu.my/id/eprint/47413/ Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial Gan, Yee Lin Lai, Oi Ming Chew, Boon How Yuen, Kah Hay Nesaretnam, Kalanithi Teng, Kim Tiu Selvaduray, Kanga Rani Meganathan, Puvaneswari Fu, Ju Yen Previous studies have reported that tocotrienols (T3) possess many distinct properties such as antioxidant, cardioprotective, neuroprotective, anti-cancer, anti-inflammatory and anti-angiogenic, which are beneficial for the improvement of human health. However, there is limited data available on the safety assessment of T3 compared to tocopherols (T). A randomised, double-blinded, cross-over and placebo-controlled human clinical trial was conducted to determine the safety and tolerance of T3 supplementation in 31 subjects with metabolic syndrome. The subjects were supplemented with tocotrienol-rich fraction (TRF) 200 mg or placebo capsules twice daily for two weeks followed by a post-intervention visit. Results showed that T3 supplementation had no significant adverse effect on the red blood cell (RBC), white blood cell (WBC) and platelet counts between TRF (5.10 ± 0.78 × 1012 litre-1, 7.35 ± 1.59 × 109 litre-1, 279.45 ± 73.86 × 109 litre-1, respectively) and placebo interventions (5.13 ± 0.76 × 1012 litre-1, 7.25 ± 1.95 × 109 litre-1, 267.45 ± 68.72 × 109 litre-1, respectively). Measures of serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT)) and albumin did not differ between TRF (25.68 ± 10.72 IU litre-1, 38.26 ± 24.74 IU litre-1, 43.61 ± 2.26 g litre-1, respectively) and placebo interventions (27.39 ± 16.44 IU litre-1, 42.23 ± 33.58 IU litre-1, 43.68 ± 2.15 g litre-1, respectively). This study indicated that supplementation with T3 at the dosage of 400 mg per day for 14 days did not induce haematoxicity and hepatotoxicity in subjects with metabolic syndrome. Malaysian Palm Oil Board 2016 Article PeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/47413/1/Safety%20assessment%20of%20tocotrienol%20supplementation%20in%20subjects%20with%20metabolic%20syndrome%20a%20randomised%20control%20trial.pdf Gan, Yee Lin and Lai, Oi Ming and Chew, Boon How and Yuen, Kah Hay and Nesaretnam, Kalanithi and Teng, Kim Tiu and Selvaduray, Kanga Rani and Meganathan, Puvaneswari and Fu, Ju Yen (2016) Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial. Journal of Oil Palm Research, 28 (1). pp. 34-43. ISSN 1511-2780 http://jopr.mpob.gov.my/safety-assessment-of-tocotrienol-supplementat-ion-in-subjects-with-metabol-ic-syndrome-a-randomised-control-trial/ |
| spellingShingle | Gan, Yee Lin Lai, Oi Ming Chew, Boon How Yuen, Kah Hay Nesaretnam, Kalanithi Teng, Kim Tiu Selvaduray, Kanga Rani Meganathan, Puvaneswari Fu, Ju Yen Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial |
| title | Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial |
| title_full | Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial |
| title_fullStr | Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial |
| title_full_unstemmed | Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial |
| title_short | Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial |
| title_sort | safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: a randomised control trial |
| url | http://psasir.upm.edu.my/id/eprint/47413/ http://psasir.upm.edu.my/id/eprint/47413/ http://psasir.upm.edu.my/id/eprint/47413/1/Safety%20assessment%20of%20tocotrienol%20supplementation%20in%20subjects%20with%20metabolic%20syndrome%20a%20randomised%20control%20trial.pdf |